ConcertAI acquires CancerLinQ to advance use of real-world evidence for oncology solutions

ConcertAI has invested in CancerLinQ, marking a significant step towards providing its members with enhanced quality reporting, industry-leading real-world data, and AI-powered solutions for more streamlined clinical trials.

ConcertaAI, one of the largest, global oncology real-world data (RWD) and quality of care technology services provider, has announced the successful acquisition of CancerLinQ, previously under the wing of the American Society of Clinical Oncology (ASCO). This strategic acquisition underscores ConcertAI’s commitment to establishing an innovative learning and research network focused on oncology, reaffirming its role as leading provider of real-world evidence (RWE) and generative AI technology solutions in the life sciences and healthcare domains.

ASCO will continue a multi-year cooperation with CancerLinQ as part of this acquisition, emphasizing their ongoing collaborative efforts. This partnership aims to build on CancerLinQ’s original 2013 mission of leveraging RWD, analytics, advanced AI, and other technologies to elevate cancer care and expedite clinical research. CancerLinQ integrates clinical data from most major electronic medical record (EMR) systems. It has an extensive network of over 100 cancer centers and practices, drawing insights from nearly seven million patient records.

ConcertAI’s commitment to healthcare innovation is highlighted by the acquisition, merging state-of-the-art technologies and data insights to drive advancements in cancer research and treatment. CancerLinQ, under this collaboration, empowers oncology care teams and researchers to innovate through technology-driven solutions.

Maintaining its focus on quality and precision medicine, CancerLinQ, in collaboration with ASCO, will prioritize the needs of oncology practices and support the expansion of the practice network. This partnership will leverage the expertise of both organizations to enhance cancer care and accelerate clinical research initiatives.

Jeff Elton, CEO of ConcertAI commented “CancerLinQ may be one of the most important oncology networks in existence. We are pleased and privileged to be able to advance the original quality improvement goals and follow-on research interests of CancerLinQ in collaboration with ASCO, with urgency and alacrity.” ConcertAI will invest over $250 million in quality solutions, data solutions, and novel clinical trial solutions to achieve the highest quality care and accelerate biomedical innovations.

ConcertAI will collaborate closely with ASCO to substantially enhance the value of CancerLinQ for oncology practices and their patients. This includes strengthening SmartLinQ™ by incorporating new data sources, making clinical trials participation more accessible through ConcertAI’s Digital Access to Clinical Trial (DACT) platform, strengthening SmartLinQ’s clinical decision support tools, and supporting automated EMR integration to seamlessly incorporate SmartLinQ into practices’ workflows.

The collaboration is poised to be transformative, positioning ConcertAI and CancerLinQ as pioneers in reshaping the landscape of oncological advancements. Their combined strengths are expected to drive significant progress in cancer care, benefiting patients, researchers, and healthcare providers. The integration represents a promising leap forward in the quest for improved outcomes and innovative solutions in oncology.